Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine, Ruxolitinib, and Venetoclax in Relapsed/Refractory T-cell Prolymphocytic Leukemia
NCT07311746Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, cladribine, venetoclax in T-cell prolymphocytic leukemia (T-PLL), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT07311746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311746.